In Arizona, the statute of limitations for Reglan (metoclopramide) tardive dyskinesia claims is generally two years from the date the injury was discovered or should have been discovered. This is based on the FDA boxed warning about the risk of tardive dyskinesia with long-term use. Consult a qualified attorney for specific deadlines.
If you or a loved one has been taking Reglan and noticed involuntary movements, you may be wondering when a formal evaluation is typically recommended. Decades of pharmacovigilance have established clear clinical guidelines for monitoring metoclopramide-related tardive dyskinesia. This page outlines the standard evaluation timeline and diagnostic criteria used by healthcare professionals.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis, but its association with tardive dyskinesia (TD) is a serious and well-documented risk. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, a potentially irreversible movement disorder characterized by involuntary movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer treatment duration and higher cumulative dosage, and Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding treatment for longer than 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD typically involves repetitive, involuntary movements such as lip smacking, grimacing, tongue protrusion, or rapid eye blinking. These movements can be disfiguring and may persist even after the drug is discontinued. The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the brain, which can lead to dopamine receptor supersensitivity over time, contributing to the development of abnormal movements. The labeling notes that metoclopramide may also suppress or partially suppress TD signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is indicated only for short-term use: 4 to 12 weeks for gastroesophageal reflux in adults who fail conventional therapy, and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling explicitly states that Reglan has not been shown to be safe or effective for gastroesophageal reflux beyond 12 weeks, and it is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may be prescribed Reglan for extended periods, increasing their exposure and risk.
For affected patients in Arizona, attorney-related considerations involve the statute of limitations for filing a claim related to Reglan-induced TD. The statute of limitations is a legal time limit within which a lawsuit must be filed. In Arizona, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury is discovered or reasonably should have been discovered. However, the timeline between exposure to Reglan and the onset of TD symptoms can complicate this. TD may develop months or even years after starting the medication, and symptoms can be subtle initially, making it difficult to pinpoint the exact date of harm. The labeling warns that metoclopramide can cause TD, and the risk increases with duration of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, patients who develop TD after prolonged Reglan use may need to establish when they first noticed symptoms or when a diagnosis was made to determine the start of the limitations period. Another key risk anchor is the adequacy of warnings provided to patients and healthcare providers. The boxed warning on Reglan's labeling is clear about the risk of TD and the need for short-term use, but patients may not have received or understood this information. If a patient was prescribed Reglan for longer than recommended without being informed of the TD risk, this could be a factor in legal claims. The labeling also advises immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to monitor or act on early symptoms may contribute to harm. In summary, Reglan's association with TD is well-established through FDA labeling, which emphasizes the importance of short-term use and monitoring. For Arizona patients, the statute of limitations for filing a claim typically runs from the discovery of the injury, but the delayed onset of TD can create challenges in timing. Patients who have developed TD after Reglan use should consult with an attorney to evaluate their specific circumstances, including the duration of treatment, the timing of symptom onset, and whether adequate warnings were provided. The evidence underscores the need for careful adherence to prescribing guidelines and prompt action if TD symptoms appear.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims, including those related to prescription drug injuries like Reglan-induced tardive dyskinesia, is generally two years from the date the injury is discovered or reasonably should have been discovered. However, because TD can develop months or years after starting Reglan, the exact timing can be complex. It is crucial to consult with an attorney to determine the applicable deadline based on your specific circumstances.
Yes, you may have a legal claim if you developed tardive dyskinesia after prolonged use of Reglan, especially if you were not adequately warned about the risk. The FDA labeling warns that Reglan should only be used for short-term treatment (4 to 12 weeks) and that the risk of TD increases with longer use. If your doctor prescribed Reglan for an extended period without proper monitoring or warning, this could be grounds for a lawsuit. An attorney can evaluate whether the statute of limitations has passed and whether the warnings provided were sufficient.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.